PPARG and metabolic dysfunction-associated steatotic liver disease: PPARγ agonists are well-known regulators of glucose and lipid metabolism (15), with established clinical applications in treating metabolic disorders such as type 2 diabetes, dyslipidemia, and non-alcoholic fatty liver disease (44).